Immunotherapy for Lung Cancer: Has it Finally Arrived?

Immunotherapy for Lung Cancer: Has it Finally Arrived?

The possible link between infection/inflammation/immune activation and a cancer patient's outcome from both a causative and outcome point of view has long been postulated. Substantial progress in the understanding of tumor-associated antigens/epitopes, immune cellular subpopulations, cytokine pathways/expression, the tumor microenvironment, and the balance between tumor-immune suppression and s...

Modeling and Simulation in Mining - Its Time Has Finally Arrived

Management decisions in aortic regurgitation: has the time for exercise assessment finally arrived?

Aortic regurgitation (AR) is a problem of moderate but increasing frequency. Current data suggest that AR of some degree affects approximately 5% to 10% of the population and increases in frequency and severity with age (1). When severe, AR gradually leads to irreversible left ventricular (LV) dysfunction, heart failure, and death; indeed, sudden death occurs in asymptomatic patients when intri...

Biomarkers for systemic lupus erythematosus: has the right time finally arrived?

The concept of ‘biomarkers’ is a concept that is, at once, old and boring yet new and exciting. The notion that pathogenesis, risk, and prognosis can be apprehended by examining discrete aspects of the underlying disease process is not new. The identification of such markers is predicated on (1) understanding the disease process; (2) identifying aspects of pathogenesis that can be reliably and ...

Why has active immunotherapy not worked in lung cancer?

Vaccines that rely on active specific stimulation of the host immune system have the potential to trigger durable antitumor responses with minimal toxicity. However, in nonsmall-cell lung cancer (NSCLC), several large phase III trials of vaccines reported within the last year have yielded disappointing results. Compared with placebo, belagenpumatucel-L (an allogenic tumor cell vaccine), tecemot...